循環腫瘤細胞在陰莖鱗狀細胞癌患者的檢測:初步研究
江佩璋、高建璋1,2、查岱龍1,2、吳勝堂1、蒙恩1、曹智惟1、陳進利1、孫光煥1、于大雄1、張聖原1、陽明昕1,2
1三軍總醫院 外科部 泌尿外科;2國防醫學院 醫學科學研究所
Detection of Circulating Tumor Cells in Patients with Penile Squamous Cell Carcinoma: A Preliminary Study
Pei-Jhang Chiang1, Chien-Chang Kao1,2, Tai-Lung Cha1,2, Sheng-Tang Wu1, En Meng1, Chih-Wei Tsao1, Chin-Li Chen1, Guang-Huan Sun1, Dah-Shyong Yu1, Sun-Yran Chang1, Ming-Hsin Yang1,2
1Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense
Medical Center, Taipei, Taiwan
2Graduate School of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
 
Objective: The study aims to investigate the presence of circulating tumor cells (CTCs) in blood samples of patients with penile squamous cell carcinoma (PSCC).
Methods: CTC analysis was performed in blood samples from 14 PSCC patients and 6 balanoposthitis patients. CTCs were isolated on the basis of cell surface marker by filtration through IsoFlux device, followed by identification according to validated morphology and immunofluorescence studies.
Results: CTCs were detected in all PSCC samples, but not in balanoposthitis samples. Immunofluorescence studies confirmed the penile origin. When PSCC patients were stratified according to the inguinal lymph node metastatic condition, a statistically significant difference was found in the number of CTCs detected.
Conclusions: Our findings provide the evidence for PSCC that CTCs may represent a useful marker to support differential diagnosis between PSCC and balanoposthitis. The correlation with some clinical parameters suggests a possible relevance of CTC analysis for prognosis and noninvasive monitoring of disease progression. Furthermore, the results suggested a potential role of CTCs for preventing overtreatment such as inguinal lymph node dissection.
 
 
    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2020-12-23 14:06:27
    最近修訂
    2020-12-24 14:03:57
    1. 1.
      Podium 01
    2. 2.
      Podium 02
    3. 3.
      Podium 03
    4. 4.
      Moderated Poster 01
    5. 5.
      Moderated Poster 02
    6. 6.
      Moderated Poster 03
    7. 7.
      Non-Discussion Poster